 |
Ophthalmic Ocular Decongestants, Anti-allergy Products
| Ophthalmic agents - Home Page |
azelastine (Optivar ®)
|
|
Relatively selective H 1 -receptor antagonist for topical administration
to the eyes. Indicated for the treatment of itching of
the eye associated with allergic conjunctivitis. ADMINISTRATION:
one drop instilled into each affected eye twice a day. [Supplied: 0.05% ophthalmic solution] |
Cromolyn sodium (Crolom ®)
|
|
Indications: Cromolyn sodium ophthalmic solution is
indicated in the treatment of vernal keratoconjunctivitis, vernal
conjunctivitis, and vernal keratitis. Symptomatic response to therapy (decreased itching, tearing, redness and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement. If required, corticosteroids may be used concomitantly with cromolyn sodium ophthalmic solution. Users of soft (hydrophilic) contact lenses should refrain from wearing lenses while under treatment with cromolyn sodium ophthalmic solution. Wear can be resumed within a few hours after discontinuation of the drug. Dosing: The dose for adults and children is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of cromolyn sodium ophthalmic solution therapy is dependent upon its administration at regular intervals, as directed. Supplied: CrolomTM (Cromolyn Sodium Ophthalmic Solution USP, 4%) |
emedastine (Emadine ®)
|
|
Emedastine is a selective H1-receptor antagonist with antiallergic and antiasthmatic properties. Dosing: Allergic conjunctivitis: 1 drop 0.05% ophthalmic solution in affected EYE(s) up to four times daily. [Supplied: 0.05% solution] . |
Epinastine
(Elestat ®)
|
|
H1 Blocker. Allergic conjunctivitis: Instill 1 drop into each eye twice
daily. Continue throughout period of exposure, even in the absence of
symptoms. Supplied: Oph solution: 0.05% (5 ml). |
Ketotifen Fumarate Ophthalmic Solution 0.025% (Zaditor
®)
|
|
Indications: Temporary
prevention of itching of the eye caused by allergic conjunctivitis.
Noncompetitive histamine antagonist (H-1 receptor) and mast cell
stabilizer. Dosing: The recommended dose is one drop in the affected eye(s) every 8 to 12 hours. Supplied: Oph solution: 0.025% (5 ml). |
Levocabastine (Livostin ®)
|
|
Indications:
temporary relief of the signs and symptoms of seasonal allergic
conjunctivitis. Dosing: The usual dose is one drop instilled in affected eyes four times per day. SHAKE WELL BEFORE USING. Supplied: [suspension: 0.05%] |
Lodoxamide tromethamine (Alomide ®)
|
|
Indications:
treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis,
vernal conjunctivitis, and vernal keratitis. Dosing: The dose for adults and children greater than two years of age is one to two drops in each affected eye four times daily for up to 3 months. Supplied: [soln: 0.1%] |
Naphazoline (Naphcon, Vasocon ®)
|
| Dosing: 1 drop every 3 to 4 hours as needed up to 4 times daily. |
Naphcon-A ® (naphazoline + pheniramine):
|
| Dosing: 1-2 drops 2 to 4 times daily as needed. |
nedocromil (Alocril ®)
|
|
Mast cell stabilizer. Indication: allergic
conjunctivitis. Dosing: Instill one or two drops in each eye twice a day. [Supplied: 2% ophthalmic soln] |
Olopatadine (Patanol ®)
|
|
Indications:
treatment of the signs and symptoms of allergic conjunctivitis. Dosing: The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours. Supplied: [0.1% soln] |
pemirolast (Alamast ®)
|
|
Mast cell stabilizer. Indication: allergic
conjunctivitis. Dosing: Instill one to two drops in each affected eye four times daily. Symptomatic response to therapy (decreased itching) may be evident within a few days, but frequently requires longer treatment (up to four weeks). Supplied: ophthalmic solution 0.1% |
 |
Disclaimer |
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
 |
 |